SLC9C1 and diabetic cardiomyopathy: Prior research has also demonstrated that empagliflozin has a considerable impact on the control of calcium ions, late sodium currents, and NHE currents, as well as the electrophysiological characteristics of diabetic cardiomyopathy [38].